|   | |
| Clinical data | |
|---|---|
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H21NO4S | 
| Molar mass | 371.45 g·mol−1 | 
| 3D model (JSmol) | |
  | |
| (verify) | |
ROD-188 is a sedative drug that was structurally derived from the GABAA antagonist bicuculline by a team at Roche. [1] Unlike bicuculline, ROD-188 acts as an agonist at GABAA receptors, being a positive allosteric modulator acting at a novel binding site distinct from those of benzodiazepines, barbiturates or muscimol, with its strongest effect produced at the α6β2γ2 subtype of the GABAA receptor. [2] ROD-188 is one of a number of related compounds acting at this novel modulatory site, some of which also act at benzodiazepine receptors. [3] [4]
| Alcohols | |
|---|---|
| Barbiturates | 
  | 
| Benzodiazepines | 
  | 
| Carbamates | |
| Flavonoids | 
  | 
| Imidazoles | |
| Kava constituents | |
| Monoureides | |
| Neuroactive steroids | 
  | 
| Nonbenzodiazepines | |
| Phenols | |
| Piperidinediones | |
| Pyrazolopyridines | |
| Quinazolinones | |
| Volatiles/gases | 
  | 
| Others/unsorted | 
 
  | 
| Ionotropic | 
  | ||||
|---|---|---|---|---|---|
| Metabotropic | 
  | ||||